ALAN I. FADEN, M.D.
Neurology at Chevy Chase Pkwy, Washington, DC
License number
DC MD19067
Category
Neurology
Type
Neurology
Address
Address
5430 Chevy Chase Pkwy NW, Washington, DC 20015
Phone
(202) 244-4490
(202) 687-4143 (Fax)
(202) 687-4143 (Fax)
Personal information
See more information about ALAN I. FADEN at radaris.comName
Address
Phone
3339 Tennyson St NW, Washington, DC 20015
6624 Barnaby St NW, Washington, DC 20015
5430 Chevy Chase Cir, Wash, DC 20015
3339 Tennyson St, Washington, DC 20015
6624 Barnaby St, Washington, DC 20015
Professional information
See more information about ALAN I. FADEN at trustoria.com
Cyclic Dipeptides And Azetidinone Compounds And Their Use In Treating Cns Injury And Neurodegenerative Disorders
Cyclic Dipeptides And Azetidinone Compounds And Their Use In Treating Cns Injury And Neurodegenerative Disorders
US Patent:
8044103, Oct 25, 2011
Filed:
Feb 22, 2007
Appl. No.:
11/709456
Inventors:
Alan P. Kozikowski - Princeton NJ, US
Alan I. Faden - Washington DC, US
Gian Luca Araldi - San Diego CA, US
Alan I. Faden - Washington DC, US
Gian Luca Araldi - San Diego CA, US
Assignee:
Georgetown University - Washington DC
International Classification:
A61K 31/12
US Classification:
514659, 514660, 514661, 514675, 514676, 514690, 514691, 544387, 548453, 548466
Abstract:
The present invention provides 4-substituted-2-azetidinone compounds, bicyclic 2-5-diketopiperazine compounds, and pharmaceutical compositions thereof that are potent, safe and effective neuroprotective agents. Due to their strong central nervous system (CNS) activity, the compounds can be used to enhance memory and to treat a variety of neurological disorders. The compounds are particularly useful for treating neurological disorders caused by, or associated with, CNS trauma.
Cyclic Dipeptides And Azetidinone Compounds And Their Use In Treating Cns Injury And Neurodegenerative Disorders
Cyclic Dipeptides And Azetidinone Compounds And Their Use In Treating Cns Injury And Neurodegenerative Disorders
US Patent:
7202279, Apr 10, 2007
Filed:
Feb 8, 1999
Appl. No.:
09/246307
Inventors:
Alan P. Kozikowski - Princeton NJ, US
Alan I. Faden - Washington DC, US
Gian Luca Araldi - San Diego CA, US
Alan I. Faden - Washington DC, US
Gian Luca Araldi - San Diego CA, US
Assignee:
Georgetown University - Washington DC
International Classification:
A61K 31/12
US Classification:
514659, 514661, 514675, 514676, 514690, 514691, 514660
Abstract:
The present invention provides 4-substituted-2-azetidinone compounds, bicyclic 2-5-diketopiperazine compounds, and pharmaceutical compositions thereof that are potent, safe and effective neuroprotective agents. Due to their strong central nervous system (CNS) activity, the compounds can be used to enhance memory and to treat a variety of neurological disorders. The compounds are particularly useful for treating neurological disorders caused by, or associated with, CNS trauma.
Narcotic Antagonists In The Therapy Of Shock
Narcotic Antagonists In The Therapy Of Shock
US Patent:
4267182, May 12, 1981
Filed:
Jan 16, 1979
Appl. No.:
6/003699
Inventors:
John W. Holaday - Rockville MD
Alan I. Faden - Washington DC
Alan I. Faden - Washington DC
Assignee:
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A01N 4342
US Classification:
424260
Abstract:
The use of narcotic antagonists (e. g. , naloxone) in shock therapy is disced.
Narcotic Antagonists In The Therapy Of Shock
Narcotic Antagonists In The Therapy Of Shock
US Patent:
4434168, Feb 28, 1984
Filed:
Mar 27, 1981
Appl. No.:
6/248622
Inventors:
John W. Holaday - Rockville MD
Alan I. Faden - Washington DC
Alan I. Faden - Washington DC
Assignee:
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A01N 4342
US Classification:
424260
Abstract:
The use of narcotic antagonists (e. g. , naloxone) in shock therapy is disclosed.